Australia’s Response to COVID-19

by | Apr 27, 2020 | Coronavirus, COVID-19, FDA, Medical Devices, Quality Systems, Requirements

Just like every other nation, Australia has also taken several measures to respond to the global pandemic. To help prevent shortages of medical equipment and personal protective equipment, the Australian regulating authority- Therapeutic Goods Administration (TGA) has announced several exemptions and expedited paths to ensure an adequate supply of medical products. Below are some exemptions and the expedited pathways that manufacturers are allowed to take in order to ramp up their production when required.

On March 22nd, 2020, TGA released the  Therapeutic Goods (Medical Devices—Accredited Pathology Laboratories) (COVID-19 Emergency) Exemption 2020 that exempted all accredited pathology laboratories from being listed on the Australian Register of Therapeutic Goods (ARTG) for COVID-19 test kits.1

TGA also released another guidance document on March 22nd, Therapeutic Goods (Medical Devices—Face Masks and Other Articles) (COVID-19 Emergency) Exemption 2020 that outlines the temporary policy for face masks and ventilators. The policy exempts disposable face masks, gloves, surgical gowns, and other PPEs from requirements such as listing in the Australian Register of Therapeutic Goods (ARTG).1 The policy published on April 8, Therapeutic Goods (Medical Devices—Ventilators) (COVID-19 Emergency) Exemption 2020 allows for Off-label use and modifications to the ventilators, anesthesia gas machines, and other devices intended for respiratory support. Local ventilator manufacturers are allowed to distribute their products provided that the devices meet the technical specifications outlined in ‘Ventilator for COVID-19 use in Australia’2 and that the following conditions are met:3

  • The manufacturer provides to the Therapeutic Goods Administration the test procedure, test results and risk analysis undertaken concerning the specified kind of medical device and a declaration that the specified kind of medical device has been manufactured following the minimum technical requirements.
  • Obtain written permission from the Therapeutic Goods Administration that, the medical device may be legally distributed.
  • Provide TGA with the information about any malfunction or deterioration in the characteristics or performance of the medical device that might lead to a serious threat to public health.
  • Submit adverse event reports to the TGA within 48 hours of becoming aware of the incident.

We here at EMMA International are closely monitoring the changing regulatory landscape and will keep you updated on how it may impact your product.

Have more questions? Call us today at 248-987-4497 or email us at info@emmainternational.com.


1Emergo (April 2020) TGA reacts to COVID-19 crisis in Australia retrieved on 04/23/2020 from  https://www.emergobyul.com/blog/2020/04/tga-reacts-covid-19-crisis-australia

2AUS TGA (April 2020) Ventilator for COVID-19 use in Australia retrieved on 04/23/2020 from https://www.tga.gov.au/sites/default/files/ventilator-covid-19-use-australia.pdf

3US TGA (April 2020) Information for clinicians on ventilators and alternative strategies when in short supply during COVID-19 retrieved on 04/23/2020 from https://www.tga.gov.au/information-clinicians-ventilators-and-alternative-strategies-when-short-supply-during-covid-19

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This